CTNPT 011: Monitoring penicillin levels for syphilis

Penicillin therapeutic drug monitoring in the treatment of infectious syphilis. Do low serum penicillin concentrations correlate with treatment failure?

About the Study

This CTN pilot study will gather data to help determine appropriate penicillin dosages for treating syphilis. The study researchers will also examine the extent to which the standard treatment of syphilis is affected by HIV co-infection. HIV-positive and HIV-negative study participants seeking treatment for syphilis will receive the Health Canada recommended dose of benzathine penicillin G (Bicillin). Study researchers will measure penicillin levels in participants blood samples and compare syphilis treatment success rates. The main purpose of the study is to determine if higher concentrations of penicillin during treatment result in better syphilis treatment results.

Background

Syphilis is a sexually transmitted infection caused by bacteria. Over the last 10 years there has been a dramatic increase in the number of reported cases of syphilis in Canada. Forty to 50 percent of individuals diagnosed with syphilis in Canada are co-infected with HIV. Penicillin has long been used to treat syphilis but according to study researchers there are no published clinical trials to guide dosing or duration of treatment. The Canadian guidelines on sexually transmitted infections (2010) recommends treatment of syphilis with Bicillin, however there is very little information on whether body mass, kidney function, or HIV infection affect treatment. The appropriate penicillin dose to treat HIV-positive individuals with syphilis remains unknown. This study seeks to begin to address these gaps.

Study Approach

This study is a non-interventional study; meaning no experimental treatment will be administered. At the time of enrolment eligible participants will receive one dose of Bicillin, which is the standard Health Canada recommended treatment for syphilis. Researchers will also draw two tubes of blood. One tube (10 mL or 2/3 Tbsp) will be taken to test for syphilis. The second tube (10 mL or 2/3 Tbsp) will be drawn to assess kidney function.

Participants are asked to return to the clinic for additional blood tests on the third and seventh day after the injection to monitor penicillin levels in the blood and then again one, three, six and 12 months later to see if the syphilis is cured. At these visits, the following assessments will be done:

One tube (10 mL or 2/3 Tbsp) of blood will be drawn and sent for syphilis testing

Adverse events will be recorded

Participants will be asked the following questions about their recent sexual behaviour in order to differentiate between treatment failure and re-infection

Number of partners

Nature of the sexual encounters (oral/anal/vaginal)

Use of safer sex practices

Eligibility Requirements

  • At least 18 years of age
  • Presenting with clinical signs of either primary or secondary syphilis; or with early latent syphilis and documented negative serology within the past 12 months
  • Positive syphilis serology (CMIA and TP-PA reactive) with a defined RPR titer at the time of diagnosis and enrolment
  • Able to provide informed consent
  • Able to communicate in either English or French
  • Able to return for follow-up

    Investigators

    Here’s who is leading this study.

    Can’t find what you’re looking for?

    Email ctninfo@ctnplus.ca.

    info@ctnplus.ca

    Participating Sites

    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999

    Ottawa Hospital General Campus

    • Dr. Paul MacPherson
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999

    Ottawa Sexual Health Clinic (SHC)

    • Site Investigator
    • 179 Clarence St Ottawa, ON
      K1N 5P7
    • (613) 563-2437

    Toronto General Hospital (TTH)

    • 585 University Avenue, 13 North
      Toronto, ON
      M5G 2N2
    • (416) 340-4800
      x6723

    Montreal Chest Institute

    • Dr. Marina Klein
    • 3650 St-Urbain street Montreal, QC
      H2X 2P4
    • (514) 843-2090
    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999
    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999
    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999
    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999
    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999
    • Site Investigator
    • 12345 Street Name,
      City Name, BC V3M 9J3
    • Contact Person
    • contact@email.com
    • 1 (604) 555-9999

    Our People

    CTN+ Researchers are the backbone of the Network through generating ideas, collaborating on new initiatives, conducting research, and sharing their knowledge.

    Explore Our Network

    Join the CTN+

    Interested in joining the CTN+? We’re always on the lookout for new members to answer the most pressing research questions of today, while anticipating the questions of tomorrow.

    Learn More